Pluripotent stem cells (embryonic stem cells, induced pluripotent stem cells) can both self-renew (divide to produce more stem cells) and differentiate into any cell type. Pluripotency is maintained by a network of transcription factors (Oct4, Sox2, Nanog) that activate pluripotency genes, silence differentiation genes, and maintain open chromatin architecture. Breaking this network (via withdrawal of cytokines like LIF, or forced expression of differentiation TFs) triggers lineage commitment. Understanding stem cell biology enables regenerative medicine and reveals how reprogramming occurs in cancer cells.
From your study of cell differentiation, you know that cells progressively narrow their identity — a fertilized egg can become anything, but a mature neuron or muscle cell is locked into its fate. Stem cells sit at the top of this hierarchy. A pluripotent stem cell retains the ability to become virtually any cell type in the body, while simultaneously being able to divide and produce more copies of itself. This dual capacity — self-renewal plus differentiation potential — is what makes stem cells biologically extraordinary and medically valuable.
The molecular basis of pluripotency centers on a small network of transcription factors, most importantly Oct4, Sox2, and Nanog. These proteins bind to thousands of gene promoters throughout the genome, activating genes that maintain the undifferentiated state and repressing genes that would trigger specialization. They also reinforce each other's expression, creating a self-sustaining feedback loop. As long as this circuit is active, the cell remains pluripotent. The chromatin itself cooperates: pluripotent cells maintain an unusually open chromatin architecture, keeping differentiation genes accessible but silent — poised to activate but held in check.
Differentiation begins when this network is disrupted. External signals — the withdrawal of growth factors like LIF (leukemia inhibitory factor) in mouse embryonic stem cells, or exposure to specific morphogens — tip the balance. Oct4 and Nanog levels fall, silenced differentiation genes become active, and the cell commits to a lineage: ectoderm, mesoderm, or endoderm. Once committed, epigenetic changes (DNA methylation, histone modification) lock in the new identity, making the transition effectively irreversible under normal conditions.
The discovery that differentiation can be reversed was transformative. In 2006, Shinya Yamanaka showed that introducing just four transcription factors (Oct4, Sox2, Klf4, and c-Myc) into ordinary adult cells could reprogram them back to a pluripotent state, creating induced pluripotent stem cells (iPSCs). This demonstrated that differentiation is not the permanent erasure of potential — it is a reversible regulatory state maintained by epigenetic controls. iPSCs open the door to patient-specific cell therapies without the ethical concerns of embryonic stem cells, and they reveal why cancer cells sometimes reactivate pluripotency genes: the same transcription factor network that maintains stem cell identity can, when aberrantly reactivated, drive uncontrolled proliferation.
No topics depend on this one yet.